Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Respiratory Infections
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Respiratory Infections
    Traditional Antibiotics for Pneumonia Can Delay Emergence of Resistant Strains - (DGNews)
    Extensively Drug-Resistant TB Can Be Managed With Aggressive Treatment Strategy - (DGNews)
    Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial - (JAMA)
    Silver-Coated Endotracheal Tubes Reduce Risk of Ventilator-Associated Pneumonia - (DGNews)
    TopAbstracts in Respiratory Infections 08/18/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Respiratory Infections
      Pharmacological Management of Coughs and Colds
      Evaluation and Management of Pneumonia in Older Adults
      The Latest on Community-Acquired Pneumonia
      Principles of Treatment of CAP - Part 2: Implications of Antimicrobial Pharmocokinetics/Pharmocodynamics
      Principles of Treatment of CAP - Part I: Implications of Antimicrobial Resistance

      Webcasts/CME archive

       Recent cases - Respiratory Infections
        Spontaneous Splenic Rupture Mimicking Pneumonia: A Case Report
        Pericardial Cyst: An Unusual Cause of Pneumonia
        Asymptomatic Stage-I Sarcoidosis Complicated By Pulmonary Tuberculosis: A Case Report
        Independent Lung Ventilation in a Newborn with Respiratory Syncytial Virus Asymmetric Acute Lung Injury: A Case Report
        Coexistence of Primary Adenocarcinoma of the Lung and Tsukamurella Pneumonia: A Case Report and Review of the Literature

        Cases archive
          




        my personal edition > respiratory infections > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        First Single-Dose Oral Antibiotic Zmax (Azithromycin Extended Release) Available in US Pharmacies for Adults with Certain Types of Sinusitis and Pneumonia

        NEW YORK, N.Y. -- August 18, 2005 -- Pfizer Inc announced today that Zmax™ (azithromycin extended release) for oral suspension, a one-dose-only treatment for mild-to-moderate acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) in adults appropriate for oral therapy, is now available by prescription in pharmacies across the United States.

        The U.S. Food and Drug Administration approved Zmax in June for the treatment of certain types of mild-to-moderate ABS and CAP in adults appropriate for oral therapy.

        Zmax provides a full course of treatment in one dose, making it easier for patients to finish their antibiotic as prescribed. Research has shown that more than 40 percent of patients fail to take all of their antibiotics as prescribed. Failure to complete therapy has been associated with treatment failure, deterioration of health, additional visits to physicians and hospital admissions, and increased medical costs. In pivotal trials, 100 percent of Zmax-treated patients completed therapy.

        "Single-dose therapy offers the potential for optimized clinical outcomes because it makes it hard for patients to skip doses or fail to complete the treatment regimen," said Dr. Michael Niederman, Chairman, Department of Medicine, Winthrop University Hospital, and Professor of Medicine, State University of New York at Stony Brook.

        In Zmax clinical studies, side effects were generally mild to moderate, and overall, the most common treatment-related adverse reactions in adult subjects were diarrhea/loose stools (11.6%), nausea (3.9%), abdominal pain (2.7%), headache (1.3%), and vomiting (1.1%). In the majority of Zmax-treated patients, diarrhea resolved within two days.

        Zmax is indicated for acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae and community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy.

        Zmax is contraindicated in patients with hypersensitivity to azithromycin, erythromycin, or any other macrolide or ketolide antibiotic. If an allergic reaction occurs, the drug should be discontinued and appropriate therapy instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy for the allergic reaction is discontinued. Pseudomembranous colitis has been reported with nearly all antibacterial agents. It is important to consider this diagnosis in patients who present with diarrhea.


        SOURCE: Pfizer Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send